Robert Ross, Clasp Therapeutics CEO

Clasp Ther­a­peu­tics emerges with $150M based on work from Bert Vo­gel­stein, Drew Par­doll

Re­searchers at Johns Hop­kins Uni­ver­si­ty have launched an­oth­er biotech that builds on more than a decade of in­ves­ti­ga­tion that they hope will im­prove T cell en­gagers and lim­it their off-tu­mor tox­i­c­i­ties.

Bert Vo­gel­stein, who found­ed com­pa­nies like Thrive and Haystack On­col­o­gy, has been work­ing with Drew Par­doll for years on mu­ta­tion-as­so­ci­at­ed neoanti­gens, or MAN­As. They formed a biotech around the idea in 2020, nam­ing it Man­aT Bio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.